Solving the Capacity Crisis for Viral Vector Manufacturing

Solving the Capacity Crisis for Viral Vector Manufacturing

Viral vectors for gene therapy have shown tremendous clinical promise which has spurred a huge increase in demand for manufacturing space, resulting in a capacity crisis. This is currently delaying the commercialization of these gene therapies for which time to market is critical.

Integrated solutions for viral vectors designed within modular cleanroom facilities streamline manufacturing and reduce time to market. Pall Biotech and G-CON manufacturing have partnered to design and deploy an integrated manufacturing solution to address the current capacity constraints for viral vector manufacturing.

Participants will learn:

  1. The manufacturing challenges facing the viral vector industry
  2. The advantages of an integrated manufacturing solution
  3. How to develop and deploy a new manufacturing facility in 10 months within a modular cleanroom

 

 

 

Moderator

 

 

Clive Glover

 

Director, Cell & Gene Therapy
Pall Biotech

Biography

 

 

 

Presenters

 

 

 

Jeremy Rautenbach

 

Global Product Manager, Integrated Solutions
Pall Biotech

Joseph Rininger

 

Director, Cell & Gene Therapy
Latham BioPharm Group

Peter Makowensky

 

Director, Sales Engineering

G-CON Manufacturing

Maximize Speed to Market Flexibility of Single-Use for Gene Therapy Manufacturing

Listen to Podcast Today

More Biotech Webinars
Our webinars keep you informed on the latest products and technologies, current industry topics, the latest trends and a range of innovations and solutions to help continuously improve your processes.
January 2022
Gene Therapy Downstream Manufacturing, Scale-up and Best Practices

Biotech | Pall Corporation webinar series

Meet the authors from the ‘Insights on Successful Gene Therapy Manufacturing and Commercialization’ ebook

Watch